Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations.

MLA

Tawfik, Haytham O., et al. “Rationale Design of Novel Substituted 1,3,5-Triazine Candidates as Dual IDH1(R132H)/ IDH2(R140Q) Inhibitors with High Selectivity against Acute Myeloid Leukemia: In Vitro and in Vivo Preclinical Investigations.” Bioorganic Chemistry, vol. 149, Aug. 2024, p. 107483. EBSCOhost, https://doi.org/10.1016/j.bioorg.2024.107483.

APA

Tawfik, H. O., Mousa, M. H. A., Zaky, M. Y., El-Dessouki, A. M., Sharaky, M., Abdullah, O., El-Hamamsy, M. H., & Al-Karmalawy, A. A. (2024). Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations. Bioorganic Chemistry, 149, 107483. https://doi.org/10.1016/j.bioorg.2024.107483

Chicago

Tawfik, Haytham O, Mai H A Mousa, Mohamed Y Zaky, Ahmed M El-Dessouki, Marwa Sharaky, Omeima Abdullah, Mervat H El-Hamamsy, and Ahmed A Al-Karmalawy. 2024. “Rationale Design of Novel Substituted 1,3,5-Triazine Candidates as Dual IDH1(R132H)/ IDH2(R140Q) Inhibitors with High Selectivity against Acute Myeloid Leukemia: In Vitro and in Vivo Preclinical Investigations.” Bioorganic Chemistry 149 (August): 107483. doi:10.1016/j.bioorg.2024.107483.